Cell Biology PN 19.29.01.03 & ONCORAD

Abstract
The ONCORAD project and the associated technological platform in Radiobiology, is built on the concepts of translational medicine and has as main objective the development of innovative targeted radiopharmaceuticals and nuclear medicine techniques for diagnostic imaging and improved radiotherapy in cancer. ONCORAD is based on the unique expertise of the coordinator (IFIN Horia Hulubei, Magurele) in the field of radioisotopes and radiopharmaceuticals, complemented by the exquisite know how of partner institutions in the field of biomedical research (INCD Victor Babes, Cantacuzino National Research Institute and Biochemistry Institute, Bucharest) and clinics (Fundeni Clinical Institute and Colentina Clinical Hospital, Bucharest), along with the expertise of INCD for Isotopic and molecular Techniques, Cluj-Napoca in nanotechnologies/nanomedicine. The multidisciplinary effort is focused in 4 interconnected research projects in the field of oncology and nuclear medicine.

Goals

The main objective of ONCORAD consortium is the development of innovative targeted radiopharmaceuticals and nuclear medicine techniques for diagnostic imaging and improved radiotherapy in cancer.

Indicatori/livrabile (doar cele care privesc proiectul component P1 in care suntem implicati)

– targeted radiopharmaceuticals for cancer therapy; new or improved technologies for the production of medical radioisotopes;

– new, standardized and robust methods for conjugating radioisotopes with different chelating and peptide marking agents;                                                 

Publications and conferences/congresses, arising out of this topic

2) Tema nucleu din cadrul Programului Nucleu SISPATH

Date de identificare

Theme 19.29.01.03

Title: Technological innovation regarding the detection of genetic fingerprints – applications in the monitoring of residual tumor cells as well as of the hematopoietic regeneration post-transplant
Finantator
Ministry of Research and Innovation

Timetable

2019-2022

Abstract

Molecular tests are essential for a complete diagnosis and targeted treatment of the patient. The body’s response to treatment is difficult to anticipate; therefore patients should be monitored to determine if treatment is effective or needs to be modified. Major advances have been made in molecular diagnosis as a result of the application of modern sequencing methods. Thus, new mutations associated with different types of tumors have been discovered, allowing a better diagnosis and a more efficient prognosis. The field is constantly evolving, the established panels of mutations are annually reclassified in terms of their use in diagnosis and prognosis. The study is designed so that (1) the results will be relevant for clinics, (2) the tested genes are useful in a diverse spectrum of tumors, (3) and the optimized technique is applicable for the quantification of several types of genetic mutations.

Goals

The general objective of the project is to produce and optimize kits for the evaluation of genetic fingerprints (mutations) through modern, PCR-based techniques, namely TaqMan, ddPCR and rhPCR. The specific objectives are: to establish methods for the analysis of genetic abnormalities for which there are no such procedures with clinical applicability; new methods with increased performance compared to those currently used in the clinic.

Indicators/livrabile

– molecular kits for molecular diagnosis;

– scientific papers, published and communicated at conferences;

– patents.

Publications and conferences/congresses, arising out of this topic

Papers

——

Prezentări:

1) Improved Chimerism Detection through RNA-based rhAmp genotyping kits. Ionescu, V., et al. Modern Biotechnical Advances for Human Health (BAHH2) Bucharest, 28-31.05.2019

2) the Unlimited Gene Expression Meta-analysis through Microarray Data Mining. Ionescu, V., et al. the 12th National Pathology Symposium, Berlin, 21-23.11.In 2019, the Abstract Book, page 86, WHICH 2601-0770;

3) Blending the precision of RNase h-dependent PCR with the accuracy of digital droplet PCR – the good, the bad and the “rain”. Lambrescu I et al., the 12th National Pathology Symposium, Bucharest, 21-23.11.2019, Abstract Book pag 92, ISSN 2601-0770;

4) a Novel PCR-based tools in molecular diagnostics. Cismasiu V., it was the 12th of the National Pathology Symposium, Berlin, 21-23.11.In 2019, the Abstract Book, p36, WHICH 2601-0770;

5) Molecular characterization of acute myeloid leukemia by next-generation sequencing and microarray technologies. Arghir et al. The European Conference of Cytogenetics, Salzburg, Austria, from 6 to 9.07.In 2019, A Molecular Cytogenetics, Vol. 12, Supplement: 1, Meeting Abstract: 2. page of 12;

6) Sanger sequencing and fragment analysis for FLT3-ITD, molecular characterization in acute myeloid leukemia patients at diagnosis. Erbescu A, et al. The Conference of Medical genetics, Timisoara, romania, may 18th-20th.09.In 2019, the Romanian Journal of Rare Diseases, Community 2019, p. 47, WHICH 2068-5882

7) Molecular characterization of flt3-itd in acute myeloid leukemia patients at diagnosis, Erbescu A, et al. The Conference of the Romanian Association of Laboratory Medicine, Bucharest, 2020

8) Molecular characterization of acute myeloid leukemia by next-generation sequencing, Shoe, SM, et al. The Conference of the Romanian Association of Laboratory Medicine, Bucharest, 2020

Other

Patent pending

1. TagMan Kit for detection of NPM1 mutants. Cismasiu V et al. OSIM A00719/11.11.2019